7 terminated. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Terminated 7 |
| Phase 2 | 1 | Terminated 1 |
Follow COVID: new trials by email Literature Review of COVID trials Research Report on COVID
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Outpatient Treatment With Anti-Coronavirus Immunoglobulin Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo - COVID, SARS-CoV2 Infection | Phase 3 | Terminated | University of Minnesota | 741 | 2021-08-06 | 2026-08-13 |
| Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID | Phase 2 / Phase 3 | Terminated | APR Applied Pharma Research s.a. | 144 | 2021-02-15 | 2023-02-03 |
| Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers Tocilizumab - COVID, SARS Pneumonia | Phase 3 | Terminated | Beneficência Portuguesa de São Paulo | 129 | 2020-05-08 | 2020-08-26 |
| Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia Convalescent anti-SARS-CoV-2 plasma, Infusion placebo - COVID, Corona Virus Infection | Phase 3 | Terminated | Thomas Benfield | 147 | 2020-05-01 | 2022-08-04 |
| MSCs in COVID-19 ARDS Remestemcel-L, Placebo - Mesenchymal Stromal Cells, Remestemcel-L | Phase 3 | Terminated | Icahn School of Medicine at Mount Sinai | 223 | 2020-04-30 | 2022-04-25 |
| Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy High-Titer COVID-19 Convalescent Plasma (HT-CCP), Standard Plasma (FFP) - COVID, Infectious Disease | Phase 3 | Terminated | Brigham and Women's Hospital | 45 | 2020-04-30 | 2021-08-13 |
| Preventing COVID-19 Complications With Low- and High-dose Anticoagulation Enoxaparin - COVID, Sars-CoV2 | Phase 3 | Terminated | University Hospital, Geneva | 160 | 2020-04-28 | 2021-09-14 |
Cytokine Release Syndrome (2) · Respiratory Distress Syndrome (2) · Acute Lung Injury (1) · COVID-19 (1) · Communicable Diseases (1) · Coronavirus Infections (1) · Dyspnea (1) · Pneumonia, Viral (1) · Thrombosis (1)
Lung Diseases (4) · Pathological Conditions, Signs and Symptoms (4) · Respiratory Tract Diseases (4) · Infections (3) · Pathologic Processes (3) · Coronaviridae Infections (2) · Inflammation (2) · Nidovirales Infections (2) · Pneumonia (2) · RNA Virus Infections (2) · Respiration Disorders (2) · Respiratory Tract Infections (2) · Shock (2) · Systemic Inflammatory Response Syndrome (2) · Virus Diseases (2)
Enoxaparin (1) · HIV hyperimmune globulin (1) · Heparin (1) · aviptadil (1) · remestemcel-l (1) · tocilizumab (1)
APR Applied Pharma Research s.a. (1) · Beneficência Portuguesa de São Paulo (1) · Brigham and Women's Hospital (1) · Icahn School of Medicine at Mount Sinai (1) · Thomas Benfield (1) · University Hospital, Geneva (1) · University of Minnesota (1)
United States (4) · Denmark (2) · Argentina (1) · Australia (1) · Brazil (1) · Greece (1) · Malaysia (1) · Mexico (1) · Peru (1) · Spain (1) · Switzerland (1) · Thailand (1) · Uganda (1) · Ukraine (1) · United Kingdom (1)
Annetine C Gelijns, PhD (1) · Cavan Reilly, PhD (1) · Clara Clausen, MD (1) · Jonathan C Javitt, MD, MPH (1) · Karen Brorup Heje Pedersen, MD (1) · Louise Thorlacius-Ussing, MD (1) · Michael Mack, MD (1) · Michaela Tinggaard, MD (1) · Nichlas Hovmand, MD (1) · Peter Smith, MD (1) · Richard Kaufman, MD (1) · Sandra Hansen, MD (1) · Simone Bastrup Israelsen, MD (1) · Viviane C Veiga, MD (1)
PMID 32407672, PMID 33472855, PMID 33502773, PMID 35244208, PMID 36180450, PMID 36216961